Tadalafil
Product Images NDC 50090-4753

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-4753). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 01)

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 02)

This is a chart displaying the changes in blood pressure (systolic and diastolic) while standing and supine for a drug (Tadalafil) compared with a placebo. The values are measured in mmHg and are presented for different time intervals (in hours).*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 03)

This is a table showing the standing and supine systolic blood pressure values (in mmHg) for participants taking Tadalafil and doxazosin or a Placebo and doxazosin combination over a 24-hour period. The time post-dose in hours is also shown.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 04)

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 05)

This is a graph displaying the concentration of Tadalafil (measured in ug/L) in plasma over a period of 120 hours after receiving a single 20mg dose, a single 5mg dose or a once-daily 5mg dose for 5 consecutive days. The concentration of Tadalafil varies over time and reaches its peak concentration between 12 to 24 hours after administration.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 06)

The text provides a comparison of the change in PSS Total Score between Tadalafil 5 mg and the Placebo treatment. The table shows that the difference is statistically significant with a p-value less than 0.01. The duration of treatment was 4-8 weeks.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 07)

This text provides results from a study comparing tadalafil 5mg with placebo, showing a significant improvement in IPSS total score in the tadalafil group compared to placebo at p<0.01. The duration of the treatment is not specified.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 08)

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 09)

The text represents the results of a study that compares the effect of Tadalafil 5mg versus a placebo on the change in IPSS total score. The data shows a significant improvement in IPSS total score with Tadalafil 5mg compared to the placebo. However, no information is available about the study design, sample size, or patient characteristics. The text only provides limited information and is not sufficient for a complete understanding of the study's results.*

FDA Label Image

Label Image (Lbl500904753)

This is a description of a medication named Tadalafil, which comes in a bottle with 90 tablets. The product number is 6879 and it needs to be stored at 8707 degrees Fahrenheit. The other text appears to be illegible characters.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.